Dimherity: Withdrawal of the marketing authorisation application
dimethyl fumarate
Table of contents
Overview
Sandoz GmbH withdrew its application for a marketing authorisation of Dimherity for the treatment of adults with relapsing remitting multiple sclerosis (MS).
The company withdrew the application on 22 February 2022.
Key facts
Name |
Dimherity |
Product number |
EMEA/H/C/006042 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
24/03/2022 |
Company making the application | |
Withdrawal type |
Initial authorisation |
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').